Avacta Group (AVCT)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

44.83p
   
  • Change Today:
    -1.67p
  • 52 Week High: 159.60
  • 52 Week Low: 44.50
  • Currency: UK Pounds
  • Shares Issued: 359.04m
  • Volume: 877,106
  • Market Cap: £160.97m
  • RiskGrade: 461
  • Beta: 0.06

Avacta clarifies reports on potential use of its Covid-19 test

By Josh White

Date: Monday 22 Feb 2021

LONDON (ShareCast) - (Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.
The AIM-traded firm said its data showed "excellent performance" of the test in identifying patients with an infectious viral load, with 96.7% sensitivity and 100% specificity using anterior nasal swab samples from 30 Covid-19 positive patients and 26 negative individuals.

It said it was now progressing to a full clinical validation with a larger number of patient samples in order to obtain a CE-mark for the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter.

"The press report this weekend incorrectly stated that a saliva-based rapid antigen test from Avacta had been evaluated at Porton Down," the company said in its statement.

"In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data outlined above.

"However, in its evaluation Porton Down used artificial samples and did not use clinical samples."

Avacta said it believed an accurate, rapid, "appropriately validated" antigen test would help to limit the spread of Covid-19, and support a "safe return" to normal life.

"In the UK, the Department of Health and Social Care is a potential customer and partner in the roll out of such a validated test.

"While Avacta continues to be in dialogue with the department, and with other organisations in the UK and abroad, with a view to future supply of its rapid antigen test, it is prioritising the full clinical validation of its nasal swab-based SARS-CoV-2 rapid antigen test as a prerequisite for CE marking and broad commercialisation."

Avacta said it would update the market through the appropriate channels as it reached significant commercial and technical milestones.

At 0837 GMT, shares in Avacta Group were up 14.45% at 209.45p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Avacta Group Market Data

Currency UK Pounds
Share Price 44.83p
Change Today -1.67p
% Change -3.58 %
52 Week High 159.60
52 Week Low 44.50
Volume 877,106
Shares Issued 359.04m
Market Cap £160.97m
Beta 0.06
RiskGrade 461

Avacta Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
34.39% below the market average34.39% below the market average34.39% below the market average34.39% below the market average34.39% below the market average
56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average
Price Trend
85.71% below the market average85.71% below the market average85.71% below the market average85.71% below the market average85.71% below the market average
52.73% below the sector average52.73% below the sector average52.73% below the sector average52.73% below the sector average52.73% below the sector average
Income Not Available
Growth
62.05% above the market average62.05% above the market average62.05% above the market average62.05% above the market average62.05% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 1
Strong Sell 0
Total 3
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Avacta Group Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
09:41 1,815 @ 44.63p
09:41 11,151 @ 44.80p
09:39 669 @ 44.80p
09:36 1,183 @ 44.85p
09:32 1,207 @ 44.80p

Avacta Group Key Personnel

CFO Tony Peter Gardiner
CEO Christina Coughlin

Top of Page